πŸ‡ΊπŸ‡Έ FDA
Patent

US 12031130

Composition for modifying target gene

granted A61KA61K31/7105A61K38/465

Quick answer

US patent 12031130 (Composition for modifying target gene) held by Takeda Pharmaceutical Company Limited expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/7105, A61K38/465, A61K47/24, A61K9/0019